Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.
Identifieur interne : 000828 ( Main/Corpus ); précédent : 000827; suivant : 000829Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.
Auteurs : S. D'Andrea ; O. Berardicurti ; A. Berardicurti ; G. Felzani ; F. Francavilla ; S. Francavilla ; R. Giacomelli ; A. BarbonettiSource :
- Spinal cord series and cases [ 2058-6124 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Anti-Bacterial Agents (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Anticoagulants (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (MeSH), Case-Control Studies (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (physiopathology), Coronavirus Infections (therapy), Drug Combinations (MeSH), Enzyme Inhibitors (therapeutic use), Female (MeSH), Heparin, Low-Molecular-Weight (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Italy (MeSH), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Oxygen Inhalation Therapy (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (physiopathology), Pneumonia, Viral (therapy), Prognosis (MeSH), Rehabilitation Centers (MeSH), Ritonavir (therapeutic use), Spinal Cord Injuries (complications), Spinal Cord Injuries (physiopathology).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antibodies, Monoclonal, Humanized, Anticoagulants, Antiviral Agents, Azithromycin, Enzyme Inhibitors, Heparin, Low-Molecular-Weight, Hydroxychloroquine, Lopinavir, Ritonavir.
- geographic : Italy.
- complications : Coronavirus Infections, Pneumonia, Viral, Spinal Cord Injuries.
- drug therapy : Coronavirus Infections.
- physiopathology : Coronavirus Infections, Pneumonia, Viral, Spinal Cord Injuries.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Betacoronavirus, Case-Control Studies, Drug Combinations, Female, Humans, Male, Middle Aged, Oxygen Inhalation Therapy, Pandemics, Prognosis, Rehabilitation Centers.
Abstract
STUDY DESIGN
Observational case-control study.
OBJECTIVE
Individuals with spinal cord injury (SCI) develop systemic physiological changes that could increase the risk of severe evolution of coronavirus disease 2019 (COVID-19) and result in atypical clinical features of COVID-19 with possible delay in both diagnosis and treatment. We evaluated differences in clinical features and evolution of COVID-19 between people with SCI and able-bodied individuals.
SETTING
The study was conducted in an Italian inpatient rehabilitation referral center for individuals with SCI during the lockdown for the COVID-19 pandemic.
METHODS
We compared clinical information between patients with SCI and able-bodied healthcare workers of the same center who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the nasopharyngeal swab polymerase chain reaction.
RESULTS
Overall, 15 out of the 25 SCI patients admitted to the center and 17 out of the 69 healthcare workers tested positive for SARS-CoV-2. Patients with SCI exhibited a significantly more advanced age and a higher prevalence of comorbidities. Nevertheless, no significant differences in clinical expression of COVID-19 and treatment strategies were observed between the two groups. All hospitalized subjects were treated in nonintensive care units and no deaths occurred in either group.
CONCLUSIONS
This study does not support the supposed notion that COVID-19 could exhibit atypical clinical features or a worse evolution in the frail population of people with SCI.
DOI: 10.1038/s41394-020-0319-0
PubMed: 32753638
PubMed Central: PMC7400746
Links to Exploration step
pubmed:32753638Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.</title><author><name sortKey="D Andrea, S" sort="D Andrea, S" uniqKey="D Andrea S" first="S" last="D'Andrea">S. D'Andrea</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy. dandrea.settimio@alice.it.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Spinal Unit, San Raffaele Institute of Sulmona, Sulmona, Italy. dandrea.settimio@alice.it.</nlm:affiliation></affiliation></author><author><name sortKey="Berardicurti, O" sort="Berardicurti, O" uniqKey="Berardicurti O" first="O" last="Berardicurti">O. Berardicurti</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Biotechnological and Clinical Applied Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Berardicurti, A" sort="Berardicurti, A" uniqKey="Berardicurti A" first="A" last="Berardicurti">A. Berardicurti</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Felzani, G" sort="Felzani, G" uniqKey="Felzani G" first="G" last="Felzani">G. Felzani</name><affiliation><nlm:affiliation>Spinal Unit, San Raffaele Institute of Sulmona, Sulmona, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Francavilla, F" sort="Francavilla, F" uniqKey="Francavilla F" first="F" last="Francavilla">F. Francavilla</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Francavilla, S" sort="Francavilla, S" uniqKey="Francavilla S" first="S" last="Francavilla">S. Francavilla</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Giacomelli, R" sort="Giacomelli, R" uniqKey="Giacomelli R" first="R" last="Giacomelli">R. Giacomelli</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Biotechnological and Clinical Applied Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Barbonetti, A" sort="Barbonetti, A" uniqKey="Barbonetti A" first="A" last="Barbonetti">A. Barbonetti</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32753638</idno><idno type="pmid">32753638</idno><idno type="doi">10.1038/s41394-020-0319-0</idno><idno type="pmc">PMC7400746</idno><idno type="wicri:Area/Main/Corpus">000828</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000828</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.</title><author><name sortKey="D Andrea, S" sort="D Andrea, S" uniqKey="D Andrea S" first="S" last="D'Andrea">S. D'Andrea</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy. dandrea.settimio@alice.it.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Spinal Unit, San Raffaele Institute of Sulmona, Sulmona, Italy. dandrea.settimio@alice.it.</nlm:affiliation></affiliation></author><author><name sortKey="Berardicurti, O" sort="Berardicurti, O" uniqKey="Berardicurti O" first="O" last="Berardicurti">O. Berardicurti</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Biotechnological and Clinical Applied Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Berardicurti, A" sort="Berardicurti, A" uniqKey="Berardicurti A" first="A" last="Berardicurti">A. Berardicurti</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Felzani, G" sort="Felzani, G" uniqKey="Felzani G" first="G" last="Felzani">G. Felzani</name><affiliation><nlm:affiliation>Spinal Unit, San Raffaele Institute of Sulmona, Sulmona, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Francavilla, F" sort="Francavilla, F" uniqKey="Francavilla F" first="F" last="Francavilla">F. Francavilla</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Francavilla, S" sort="Francavilla, S" uniqKey="Francavilla S" first="S" last="Francavilla">S. Francavilla</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Giacomelli, R" sort="Giacomelli, R" uniqKey="Giacomelli R" first="R" last="Giacomelli">R. Giacomelli</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Biotechnological and Clinical Applied Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Barbonetti, A" sort="Barbonetti, A" uniqKey="Barbonetti A" first="A" last="Barbonetti">A. Barbonetti</name><affiliation><nlm:affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Spinal cord series and cases</title><idno type="eISSN">2058-6124</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Anticoagulants (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (physiopathology)</term><term>Coronavirus Infections (therapy)</term><term>Drug Combinations (MeSH)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female (MeSH)</term><term>Heparin, Low-Molecular-Weight (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Italy (MeSH)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Oxygen Inhalation Therapy (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (physiopathology)</term><term>Pneumonia, Viral (therapy)</term><term>Prognosis (MeSH)</term><term>Rehabilitation Centers (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>Spinal Cord Injuries (complications)</term><term>Spinal Cord Injuries (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antibodies, Monoclonal, Humanized</term><term>Anticoagulants</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Enzyme Inhibitors</term><term>Heparin, Low-Molecular-Weight</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Italy</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Spinal Cord Injuries</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Spinal Cord Injuries</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Betacoronavirus</term><term>Case-Control Studies</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Oxygen Inhalation Therapy</term><term>Pandemics</term><term>Prognosis</term><term>Rehabilitation Centers</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>STUDY DESIGN</b></p><p>Observational case-control study.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>Individuals with spinal cord injury (SCI) develop systemic physiological changes that could increase the risk of severe evolution of coronavirus disease 2019 (COVID-19) and result in atypical clinical features of COVID-19 with possible delay in both diagnosis and treatment. We evaluated differences in clinical features and evolution of COVID-19 between people with SCI and able-bodied individuals.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>The study was conducted in an Italian inpatient rehabilitation referral center for individuals with SCI during the lockdown for the COVID-19 pandemic.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We compared clinical information between patients with SCI and able-bodied healthcare workers of the same center who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the nasopharyngeal swab polymerase chain reaction.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Overall, 15 out of the 25 SCI patients admitted to the center and 17 out of the 69 healthcare workers tested positive for SARS-CoV-2. Patients with SCI exhibited a significantly more advanced age and a higher prevalence of comorbidities. Nevertheless, no significant differences in clinical expression of COVID-19 and treatment strategies were observed between the two groups. All hospitalized subjects were treated in nonintensive care units and no deaths occurred in either group.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>This study does not support the supposed notion that COVID-19 could exhibit atypical clinical features or a worse evolution in the frail population of people with SCI.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32753638</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2058-6124</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>08</Month><Day>04</Day></PubDate></JournalIssue><Title>Spinal cord series and cases</Title><ISOAbbreviation>Spinal Cord Ser Cases</ISOAbbreviation></Journal><ArticleTitle>Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.</ArticleTitle><Pagination><MedlinePgn>69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41394-020-0319-0</ELocationID><Abstract><AbstractText Label="STUDY DESIGN">Observational case-control study.</AbstractText><AbstractText Label="OBJECTIVE">Individuals with spinal cord injury (SCI) develop systemic physiological changes that could increase the risk of severe evolution of coronavirus disease 2019 (COVID-19) and result in atypical clinical features of COVID-19 with possible delay in both diagnosis and treatment. We evaluated differences in clinical features and evolution of COVID-19 between people with SCI and able-bodied individuals.</AbstractText><AbstractText Label="SETTING">The study was conducted in an Italian inpatient rehabilitation referral center for individuals with SCI during the lockdown for the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS">We compared clinical information between patients with SCI and able-bodied healthcare workers of the same center who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the nasopharyngeal swab polymerase chain reaction.</AbstractText><AbstractText Label="RESULTS">Overall, 15 out of the 25 SCI patients admitted to the center and 17 out of the 69 healthcare workers tested positive for SARS-CoV-2. Patients with SCI exhibited a significantly more advanced age and a higher prevalence of comorbidities. Nevertheless, no significant differences in clinical expression of COVID-19 and treatment strategies were observed between the two groups. All hospitalized subjects were treated in nonintensive care units and no deaths occurred in either group.</AbstractText><AbstractText Label="CONCLUSIONS">This study does not support the supposed notion that COVID-19 could exhibit atypical clinical features or a worse evolution in the frail population of people with SCI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Andrea</LastName><ForeName>S</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5031-031X</Identifier><AffiliationInfo><Affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy. dandrea.settimio@alice.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Unit, San Raffaele Institute of Sulmona, Sulmona, Italy. dandrea.settimio@alice.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berardicurti</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Biotechnological and Clinical Applied Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berardicurti</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felzani</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Spinal Unit, San Raffaele Institute of Sulmona, Sulmona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francavilla</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francavilla</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacomelli</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Biotechnological and Clinical Applied Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbonetti</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Andrology Unit, Department of Life, Health and Environment Sciences, University of L'Aquila, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Spinal Cord Ser Cases</MedlineTA><NlmUniqueID>101680856</NlmUniqueID><ISSNLinking>2058-6124</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="Y">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012047" MajorTopicYN="N">Rehabilitation Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32753638</ArticleId><ArticleId IdType="doi">10.1038/s41394-020-0319-0</ArticleId><ArticleId IdType="pii">10.1038/s41394-020-0319-0</ArticleId><ArticleId IdType="pmc">PMC7400746</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):470-473</Citation><ArticleIdList><ArticleId IdType="pubmed">31986257</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 2010 Apr 12;317(1-2):14-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20035825</ArticleId></ArticleIdList></Reference><Reference><Citation>J Spinal Cord Med. 2014 Jan;37(1):32-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord Ser Cases. 2020 Apr 17;6(1):22</Citation><ArticleIdList><ArticleId IdType="pubmed">32303672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Oct 20;370(9596):1453-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Spinal Cord Med. 2016 May;39(3):246-52</Citation><ArticleIdList><ArticleId IdType="pubmed">26312544</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2013 Nov 19;81(21):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24153440</ArticleId></ArticleIdList></Reference><Reference><Citation>Disabil Rehabil. 2007 Dec 30;29(24):1926-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17852230</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord. 2020 May;58(5):517-519</Citation><ArticleIdList><ArticleId IdType="pubmed">32346122</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Phys Med Rehabil. 2001 May;82(5):589-96</Citation><ArticleIdList><ArticleId IdType="pubmed">11346833</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord Ser Cases. 2020 May 13;6(1):39</Citation><ArticleIdList><ArticleId IdType="pubmed">32404896</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord Ser Cases. 2020 May 13;6(1):38</Citation><ArticleIdList><ArticleId IdType="pubmed">32404880</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrology. 2020 May 20;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32436355</ArticleId></ArticleIdList></Reference><Reference><Citation>QJM. 2001 Oct;94(10):521-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11588210</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101623</Citation><ArticleIdList><ArticleId IdType="pubmed">32179124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2013 Aug 20;81(8):723-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23884034</ArticleId></ArticleIdList></Reference><Reference><Citation>J Spinal Cord Med. 2019 Jan;42(1):86-93</Citation><ArticleIdList><ArticleId IdType="pubmed">29323633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Spinal Cord Med. 2016 Jul;39(4):443-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25614040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discov. 2020 Jun;10(6):779-782</Citation><ArticleIdList><ArticleId IdType="pubmed">32276929</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord Ser Cases. 2020 May 11;6(1):35</Citation><ArticleIdList><ArticleId IdType="pubmed">32393767</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord. 1997 May;35(5):266-74</Citation><ArticleIdList><ArticleId IdType="pubmed">9160449</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Med Child Neurol. 2009 Oct;51 Suppl 4:64-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19740212</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord. 2009 Oct;47(10):757-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19350042</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinal Cord. 2005 Jul;43(7):408-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15711609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1994 Nov;47(11):1245-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7722560</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000828 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000828 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32753638
|texte= Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32753638" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |